eGenesis
also invests · investor profileFounded 2015 · 154 employees on LinkedIn · 6 known investors
eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
Founders & leadership
MC
Mike Curtis, Ph.D.President & Chief Executive Officer
Investors · 6
Competitors · 3
by search overlapOrgenesis32 shared keywordsOrgenesis provides decentralized manufacturing infrastructure for cell and gene therapies, enabling on-site processing of CGTs in regional centers through its POCare™ platform and OMPUL™ mobile processing units. The company aims to reduce costs, shorten development timelines, and improve patient access to personalized cell and gene therapies.
Genesis Molecular AI23 shared keywordsGenesis develops GEMS, an AI platform for drug discovery that identifies and optimizes drug candidates. The company partners with pharmaceutical firms like Incyte and Gilead to accelerate the identification and optimization of new drugs.
LeadIQ16 shared keywordsLeadIQ offers a company search tool that provides B2B company profiles with data such as revenue, employee count, funding, and contact information to help sales teams find decision makers and build pipeline.
Companies competing with eGenesis for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does eGenesis do?
- eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
- Who are eGenesis's investors?
- eGenesis's investors include Alta Partners, Altium Capital, Eisai Innovation, Inc., Fresenius Medical Care Ventures, Khosla Ventures, Lux Capital.